National Cancer Institute (NCI): Leukemia, Myelomonocytic, Chronic trials

The registry lists 43 Leukemia, Myelomonocytic, Chronic studies with National Cancer Institute (NCI) as lead sponsor. 1 are open to participants now and 14 have results posted.

Phase 1 22Phase 2 22Phase 3 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesRecruitingNCT06904066Phase 1
• Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related ChangesActive, not recruitingNCT04802161Phase 2Results posted
• Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT03289910Phase 2Results posted
• Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological MalignanciesCompletedNCT01789255Phase 2Results posted
• Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT01522976Phase 2Results posted
• Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow TransplantationCompletedNCT01338987Phase 2Results posted
• Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and AnemiaActive, not recruitingNCT00843882Phase 3Results posted
• Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid LeukemiaCompletedNCT00666588Phase 2Results posted
• Aflibercept in Treating Patients With Myelodysplastic SyndromesTerminatedNCT00509249Phase 2Results posted
• MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic LeukemiaCompletedNCT00462605Phase 2Results posted
• Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic LeukemiaCompletedNCT00451048Phase 2Results posted
• Sunitinib in Treating Patients With Idiopathic MyelofibrosisTerminatedNCT00387426Phase 2Results posted
• 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00381550Phase 2Results posted
• Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid LeukemiaCompletedNCT00313586Phase 2Results posted
• Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid LeukemiaCompletedNCT00096122Phase 1/2Results posted
• Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative NeoplasmActive, not recruitingNCT05600894Phase 2
• Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative DisordersCompletedNCT02210858Phase 1/2
• Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT02029950Phase 1
• Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT01757639Phase 1
• MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedNCT01231919Phase 1
• Veliparib and Temozolomide in Treating Patients With Acute LeukemiaCompletedNCT01139970Phase 1
• Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
• Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative DisordersCompletedNCT00588991Phase 1
• Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid LeukemiaActive, not recruitingNCT00392353Phase 1/2
• Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other DiseasesCompletedNCT00357708Phase 1
• Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative DisordersCompletedNCT00357305Phase 1
• Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other DiseasesCompletedNCT00351975Phase 1
• MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid LeukemiaCompletedNCT00101179Phase 1
• Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic SyndromesCompletedNCT00098423Phase 1
• Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT00096148Phase 2
• XK469R in Treating Patients With Refractory Hematologic CancerCompletedNCT00095797Phase 1
• Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00087204Phase 1
• CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic PhaseCompletedNCT00084916Phase 2
• Imatinib Mesylate in Treating Patients With MyelofibrosisCompletedNCT00039416Phase 2
• Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00025415Phase 1
• Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic LeukemiaCompletedNCT00025038Phase 2
• Thalidomide in Treating Patients With Myelodysplastic SyndromeCompletedNCT00015990Phase 2
• Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid CancerCompletedNCT00012376Phase 1
• Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00006363Phase 3
• Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial TherapyCompletedNCT00005942Phase 1/2
• Tipifarnib in Treating Patients With Myelodysplastic SyndromesCompletedNCT00005845Phase 1
• Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced CancerCompletedNCT00003451Phase 1
• Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic SyndromeCompletedNCT00002798Phase 3